Solid Biosciences Reports $45.8 Million Net Loss in Q3 2025, Increases R&D Spending

Solid Biosciences Inc. reported a net loss of $45.8 million for the third quarter of 2025, compared to a loss of $32.7 million in the same period of 2024, marking a 39.9% increase in losses year-over-year. For the nine months ending September 30, 2025, the company recorded a net loss of $124.5 million, up from $82.1 million in the prior year, reflecting a 51.7% increase. The company's total operating expenses for the third quarter were $48.1 million, a 36.6% rise from $35.2 million in the previous year, driven primarily by increased research and development costs associated with its gene therapy candidates.

Research and development expenses surged to $38.9 million in the third quarter of 2025, up 42.2% from $27.3 million in the same quarter of 2024. This increase was largely attributed to a $12.8 million rise in costs related to SGT-003, which is in clinical trials for Duchenne muscular dystrophy. General and administrative expenses also increased by 17.1% to $9.2 million, primarily due to higher personnel costs and legal fees. The company’s total cash, cash equivalents, and available-for-sale securities stood at $236.1 million as of September 30, 2025, providing a financial cushion to support ongoing operations.

In terms of strategic developments, Solid Biosciences has made significant progress in its clinical trials. The Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 began participant dosing in the second quarter of 2024, with 23 participants dosed as of October 31, 2025. The company has also initiated the IMPACT DUCHENNE trial, a Phase 3 study for SGT-003 outside the U.S., and activated the first clinical trial site for SGT-212, which is aimed at treating Friedreich’s ataxia. The FDA has granted Fast Track and Rare Pediatric Disease designations for both SGT-003 and SGT-212, indicating the agency's recognition of the potential therapeutic benefits of these candidates.

Operationally, Solid Biosciences has expanded its workforce and capabilities to support its growing pipeline. The company reported an increase in personnel-related expenses, reflecting its commitment to hiring additional staff to facilitate clinical development and regulatory interactions. The company’s focus on advancing its gene therapy candidates is underscored by its ongoing efforts to establish collaborations and partnerships that could enhance its research and development capabilities.

Looking ahead, Solid Biosciences anticipates continued operating losses as it invests heavily in the development of its gene therapy candidates. The company expects that its current cash reserves will be sufficient to fund operations into the first half of 2027, but acknowledges the need for additional funding to support its long-term objectives. The company remains focused on advancing its clinical trials and achieving regulatory approvals, while also monitoring market conditions and potential strategic partnerships to bolster its financial position.